Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Unicycive Therapeutics (UNCY) Revenue (2022 - 2023)

Unicycive Therapeutics filings provide 2 years of Revenue readings, the most recent being $675000.0 for Q1 2023.

  • On a quarterly basis, Revenue changed N/A to $675000.0 in Q1 2023 year-over-year; TTM through Dec 2023 was $675000.0, a N/A change, with the full-year FY2023 number at $675000.0, down 29.02% from a year prior.
  • Revenue hit $675000.0 in Q1 2023 for Unicycive Therapeutics, down from $951000.0 in the prior quarter.
  • In the past five years, Revenue ranged from a high of $951000.0 in Q3 2022 to a low of $675000.0 in Q1 2023.